Volume 1, Issue 1 (2021)

Insights into Immunotherapy Administration During the COVID-19 Pandemic: Experience from an Indian Tertiary Care Center

Written by Abhishek Pathak Published on Vol 1 Issue 1, 2021

The COVID‑19 outbreak has been a scourge for cancer patients. The absence of knowledge and ignorance in addressing cancer patients throughout this epidemic has deteriorated their illnesses. Gathering information about patients undergoing immunotherapy during the COVID-19 pandemic was the study's goal. The information gathered covered the diagnosis, some research, and the effects of the immunotherapy medications as well as their adverse effects. To examine the actual situation, we looked at 1

A Rare Case of Maxillary Ameloblastoma with Pulmonary Metastasis

Written by Karpal Singh Sohal Published on Vol 1 Issue 1, 2021

Low-grade odontogenic epithelial neoplasms, known as ameloblastomas, account for approximately 10% of odontogenic tumors and 1% of all oral malignancies. In rare cases, these tumors may spread to distant locations; if this occurs, they are called metastatic ameloblastomas. This article describes a case of an unusual type of maxillary ameloblastoma with lung metastasis and the challenges of managing it in resource-limited settings. In 2018, a 24-year-old African man presented with a significant s

Intertrigo-Like Eruption Induced by Cetuximab: A Novel EGFR Inhibitor-Associated Toxicity

Written by Rosa Coppola Published on Vol 1 Issue 1, 2021

Targeted therapy has emerged as one of the most significant developments in cancer treatment in recent years. Patients with advanced, recurring, or metastatic cancer are treated with agents that target the epidermal growth factor receptor (EGFR). One of the most prevalent adverse reactions of EGFR inhibitors is skin damage. We report on a 70-year-old male patient with metastatic colorectal cancer who experienced an intertrigo-like eruption while receiving topical corticosteroid treatment as part

The Predictive Role of Sarcopenia in Lung Adenocarcinoma Patients Treated with Erlotinib

Written by Havva Yesil Cinkir Published on Vol 1 Issue 1, 2021

In advanced non-small cell lung cancer (NSCLC), factors such as susceptibility to epidermal growth factor receptor tyrosine kinase inhibitors with pathological subtype of adenocarcinoma, smoking history, and female gender are predictive. However, we need novel predictive markers as well as driver mutations for improved therapy choices. The present study aimed to investigate the prognostic significance of sarcopenia in lung adenocancer patients treated with erlotinib. Skeletal muscle index (SMI)

Obstacles in Enrolling Men under Active Surveillance for Prostate Cancer in Clinical Chemoprevention Studies

Written by J. Van Der Merwe Published on Vol 1 Issue 1, 2021

Clinical trials are fundamental to evidence-based medicine, as they employ rigorous scientific methods to evaluate the efficacy and safety of new therapies aimed at preventing or treating diseases, including cancer. Successful completion of these trials relies heavily on participant enrollment. Although over 70% of Americans express willingness to participate in clinical trials, fewer than 5% of adult cancer patients actually enroll, highlighting a substantial gap between intent and participatio

Assessment of Early Cardiac Dysfunction Related to Cancer Therapy in Patients Receiving Hematopoietic Stem Cell Transplantation: An Echocardiographic Analysis

Written by L. Wang Published on Vol 1 Issue 1, 2021

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for various blood cancers, but it carries a risk of developing cardiac dysfunction related to cancer therapy. This study aimed to investigate the occurrence of subclinical cancer therapy-related cardiac dysfunction (CTRCD) one year after HSCT and to explore clinical factors that may contribute to its development. The study included 55 patients who underwent either autologous or allogeneic HSCT. Echocardiographic evaluations

Influence of Global Health Status, Communication Satisfaction, and Timing on Decisional Conflict Following Consideration of Early Phase Clinical Cancer Trial Participation

Written by K.H. Liew Published on Vol 1 Issue 1, 2021

When conventional treatments are no longer effective, patients with advanced cancer may consider enrolling in early-phase clinical trials. The process of deciding on participation is often complex, and supporting patients in this process could enhance their quality of life. This multicenter prospective study explored factors contributing to decisional conflict—a reflection of decision-making quality—in patients who recently made a choice about joining phase I or I/II trials. We examined whether

Germany’s Population-Level Cancer Registry for Clinical Data

Written by M. Petrovic Published on Vol 1 Issue 1, 2021

In 2013, a federal mandate required all German states to collect additional clinical information within population-based cancer registries to actively monitor and enhance cancer care quality, improve transparency, and support health research. A decade later, we present the current state of this expanded cancer registration, including recent statistics on cancer in Germany. Cancer reporting is compulsory for physicians, with each case typically generating 5–10 reports from various healthcare prov

Optimal Timing for Lymphadenectomy in Non-Metastatic Pancreatic Neuroendocrine Tumors: Insights from a Population-Based Study by the German Clinical Cancer Registry Group

Written by K. Meyer Published on Vol 1 Issue 1, 2021

Determining which patients should undergo lymphadenectomy remains a debated issue in the management of pancreatic neuroendocrine tumors (pNETs), particularly with the increasing adoption of parenchyma-sparing and minimally invasive surgical techniques. This study utilized data from the German Cancer Registry Group, encompassing cases between 2000 and 2021. Only patients who underwent upfront resection for non-functional, non-metastatic pNETs were included. Among 5520 recorded pNET cases, 1006 fu

Childhood Gastric Carcinoma: Epidemiology and Clinical Features Based on Population and Clinical Cancer Registry Data

Written by T. Schmid Published on Vol 1 Issue 1, 2021

Gastric carcinoma is an extremely uncommon malignancy in children, and knowledge regarding its causes, epidemiology, and clinical presentation in the pediatric population remains limited. This study aimed to expand the understanding of the occurrence and characteristics of childhood gastric carcinoma. Cases of gastric carcinoma diagnosed between 2000 and 2017/2018 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database and the German Center for Cancer Registry Data. Pa

Preclinical Mouse Models for Cancer Immunotherapy with Anti-PD-1 Highlight the Importance of Using Mouse-Specific Reagents to Reflect Clinical Settings

Written by T. Sato Published on Vol 1 Issue 1, 2021

Immune checkpoint inhibition (ICI) has become a highly effective strategy for reversing cancer-induced immune suppression. Monoclonal antibodies (mAbs) targeting PD-1/PD-L1 are FDA-approved and increasingly used in clinical practice. However, preclinical mouse models have struggled to replicate the significant therapeutic responses and toxicities seen in patients. This discrepancy is largely due to commonly used models, which rely on fast-growing, ex vivo–cultured transplantable tumor cell lines

Volume 1, Issue 1 (2021)

About GalaxyPub